Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/4/2017
SIETES contiene 91761 citas

 
 
 1 a 20 de 509 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Grosser T. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2017;376:1389-90. [Ref.ID 101526]
2.
Felson DT. Safety of nonsteroidal antiinflammatory drugs.. N Engl J Med 2016;373:2595-6. [Ref.ID 101348]
3. Cita con resumen
Anónimo. Celecoxib safety revisited. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:159. [Ref.ID 101041]
4.Tiene citas relacionadas Cita con resumen
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckeman B, Berger MF, Bao W, Lincoff AM, for the PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;373:2519-29. [Ref.ID 101038]
5.Enlace a cita original Cita con resumen
7. Cita con resumen
Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016:14 de abril. [Ref.ID 100161]
9.Tiene citas relacionadas Cita con resumen
Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, for the AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015;314:151-61. [Ref.ID 99346]
10.Tiene citas relacionadas Cita con resumen
Winkelmayer WC. Treatment of hyperkalemia: from "hyper K" striketout to home run?. JAMA 2015;314:129-30. [Ref.ID 99345]
11.Tiene citas relacionadas
Greenland P, Lauer MS. Cholesterol lowering in 2015: still answering questions about how in whom. JAMA 2015;314:127-8. [Ref.ID 99344]
12.Enlace a cita original Cita con resumen
Caldeira D, Gonçalves N, Pinto FJ, Costa J, Ferreira J. Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2015;24:757-64. [Ref.ID 99318]
13. Cita con resumen
Nadeem S, Hashmat S, Defreitas MJ, Westreich KD, Shatat IF, Selewski DT, Onder AM, Chiang M, Weaver DJ Jr, Steinke J, Barcia J, Hernández J, Hildalgo G, Ingraham SE, Abitbol CL, Pan C, Greenbaum LA. Renin angiotensin system blocker fetopathy: a midwest pediatric nephrology consortium report. J Pediatr 2015;167:881-5. [Ref.ID 99266]
14.Tiene citas relacionadas Cita con resumen
Ingelfinger JR. A new era for the treatment of hyperkalemia?. N Engl J Med 2015;372:275-7. [Ref.ID 98736]
15.Tiene citas relacionadas Cita con resumen
Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015;372:222-31. [Ref.ID 98734]
16.Tiene citas relacionadas Cita con resumen
Weir MR, Bakris GL, Bushinsky DA, Garza DG, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, for the OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalaemia receiving RAAS inhibitors. N Engl J Med 2015;372:211-21. [Ref.ID 98710]
17. Cita con resumen
Anónimo. FDA approves anti-clotting drug Savaysa. FDA U.S. Food and Drug Administration 2015:8 de enero. [Ref.ID 98703]
18. Cita con resumen
Anónimo. Interferon beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome. Drug Safety Update 2014;8:A1. [Ref.ID 98101]
19. Cita con resumen
Wright DFB, Al-Sallami HS, Duffull SB. Is the dose of dabigatran really more predictable than warfarin?. Br J Clin Pharmacol 2013;76:997-8. [Ref.ID 96634]
20.Tiene citas relacionadas
de Zeeuw D. The end of dual therapy with renin-angiotensin-aldosterone system blockade?. N Engl J Med 2013;369:1960-2. [Ref.ID 96540]
Seleccionar todas
 
 1 a 20 de 509 siguiente >>